Schrodinger (STU:43Z) ROCE % : -14.31% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Schrodinger ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Schrodinger's annualized ROCE % for the quarter that ended in Dec. 2024 was -14.31%.

Schrodinger ROCE % Historical Data

The historical data trend for Schrodinger's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger ROCE % Chart

Schrodinger Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-15.35

-17.27

-24.40

-28.03

-32.85

Schrodinger Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-17.25	-41.55	-34.75	-46.98	-14.31

Schrodinger ROCE % Calculation

Schrodinger's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-199.878	/	( ( (736.31 - 122.578)	+	(786.181 - 183.118) )	/ 2 )
	=	-199.878	/	( (613.732	+	603.063)	/ 2 )
	=	-199.878	/	608.3975
	=	-32.85 %

Schrodinger's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-79.12	/	( ( (603.036 - 100.116)	+	(786.181 - 183.118) )	/ 2 )
	=	-79.12	/	( ( 502.92	+	603.063 )	/ 2 )
	=	-79.12	/	552.9915
	=	-14.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Schrodinger (STU:43Z) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Schrodinger ROCE % Related Terms

Thank you for viewing the detailed overview of Schrodinger's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Schrodinger Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (STU:43Z) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SDGR:USA

Address

1540 Broadway, 24th Floor, New York, NY, USA, 10036

Website

https://www.schrodinger.com

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Headlines

No Headlines